Ovarian cancer is one of the most common gynecological malignancies leading to one of the highest causes of cancer-related deaths in women worldwide. Approximately over 250,000 women are diagnosed globally and over 150,000 patients pass due to this disease annually. It has been found approximately 90% of ovarian cancer cases are epithelial ovarian cancer. Surgical treatment is typically performed for early ovarian cancer to remove the tumor and make a definite diagnosis and to classify the stage of the disease. Cytoreductive surgery combined with platinum-based chemotherapy is commonly used for advanced ovarian cancer patients and despite the short-time effect, approximately 70% of patients suffer from recurrence after first-line treatment which negatively impacts survival time and prognosis. Systematic lymph node dissection (SLND) is also one of the most common procedures which include pelvic and para-aortic lymphadenectomy in early stages. Ongoing studies in the early stages of epithelial ovarian cancer are evaluating SLND that could potentially help obtain a sufficient number of lymph nodes to identify occult lymph node metastases and therefore guide potential chemotherapy decisions by accurate staging.
Ovarian cancer requires the identification of potential therapies and treatments for ovarian cancer to improve the survival rate and prognosis of the disease. However, studies have demonstrated that therapies and treatments can be influenced by molecular mechanisms that need to be further studied. Studies have found that an active therapeutic target for combination treatment was found to be the DNA damage response pathway, such as Poly (ADP-ribose) polymerase (PARP). PARP inhibitors have been found to cause DNA damage via the catalytic inhibition of the PARP enzyme resulting in strengthening the killing of tumor cells. Further studies have explored the role of Acyl-CoA medium-chain synthetase-3 (ACSM3), which is a sub-unit of CoA ligases known to influence the progression of many diseases. ACSM3 has been found to be differentially expressed in multiple cancers which influence poor prognosis and low survival rates. ACSM3 has been found to be down-regulated in ovarian cancer which reflects poor survival as it influences cell migration, proliferation and invasion of ovarian cancer cells. Studies have also demonstrated that ITG β1 (Integrin β1) expressed an upregulation in ovarian cancer tissues and the overexpression was associated with poor prognosis in addition to a more advanced stage of the disease.
Further research is required to identify and establish potential molecular factors which influence the treatment and therapies of ovarian cancer. This Research Topic aims to generate a discussion around the research regarding molecular influences in ovarian cancer. We welcome Original Research Articles, Review Articles, Systematic Reviews and Mini Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Ovarian cancer is one of the most common gynecological malignancies leading to one of the highest causes of cancer-related deaths in women worldwide. Approximately over 250,000 women are diagnosed globally and over 150,000 patients pass due to this disease annually. It has been found approximately 90% of ovarian cancer cases are epithelial ovarian cancer. Surgical treatment is typically performed for early ovarian cancer to remove the tumor and make a definite diagnosis and to classify the stage of the disease. Cytoreductive surgery combined with platinum-based chemotherapy is commonly used for advanced ovarian cancer patients and despite the short-time effect, approximately 70% of patients suffer from recurrence after first-line treatment which negatively impacts survival time and prognosis. Systematic lymph node dissection (SLND) is also one of the most common procedures which include pelvic and para-aortic lymphadenectomy in early stages. Ongoing studies in the early stages of epithelial ovarian cancer are evaluating SLND that could potentially help obtain a sufficient number of lymph nodes to identify occult lymph node metastases and therefore guide potential chemotherapy decisions by accurate staging.
Ovarian cancer requires the identification of potential therapies and treatments for ovarian cancer to improve the survival rate and prognosis of the disease. However, studies have demonstrated that therapies and treatments can be influenced by molecular mechanisms that need to be further studied. Studies have found that an active therapeutic target for combination treatment was found to be the DNA damage response pathway, such as Poly (ADP-ribose) polymerase (PARP). PARP inhibitors have been found to cause DNA damage via the catalytic inhibition of the PARP enzyme resulting in strengthening the killing of tumor cells. Further studies have explored the role of Acyl-CoA medium-chain synthetase-3 (ACSM3), which is a sub-unit of CoA ligases known to influence the progression of many diseases. ACSM3 has been found to be differentially expressed in multiple cancers which influence poor prognosis and low survival rates. ACSM3 has been found to be down-regulated in ovarian cancer which reflects poor survival as it influences cell migration, proliferation and invasion of ovarian cancer cells. Studies have also demonstrated that ITG β1 (Integrin β1) expressed an upregulation in ovarian cancer tissues and the overexpression was associated with poor prognosis in addition to a more advanced stage of the disease.
Further research is required to identify and establish potential molecular factors which influence the treatment and therapies of ovarian cancer. This Research Topic aims to generate a discussion around the research regarding molecular influences in ovarian cancer. We welcome Original Research Articles, Review Articles, Systematic Reviews and Mini Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.